
At a time when the pandemic seemed to have receded into the background, a new sub-variant of COVID-19 has regained the attention of global health authorities.
It is about the BA.3.2 variant, otherwise known as "Cicada", part of the Omicron variant family.
This variant is being closely monitored by institutions such as the World Health Organization and the Centers for Disease Control and Prevention, especially due to its spread in several countries, including the United States and Thailand. However, experts emphasize that there is no room for panic.
According to current data, “Cicada” appears to behave similarly to previous Omicron variants. In most cases, infection presents with mild or moderate symptoms, and no significant increase in severe cases or hospitalizations has been observed.
The most common symptoms include mild fever, sore throat, fatigue, cough, and runny nose, a clinical picture already familiar to the public from previous waves of the pandemic.
Although its rapid spread to more than 20 countries has attracted the attention of the scientific community, there are no indications so far that this variant poses a higher risk to public health compared to its predecessors.
Health authorities continue to call for vigilance and monitoring of the situation, emphasizing that the evolution of the virus remains unpredictable. At this stage, "Cicada" is seen more as a development to follow than a serious new threat.